Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | USP3 | Q9Y6I4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545032 | 0.88 | MAPK11 (0.53) | CNR1MAPK11MAPK14MAPK1IKBKB | |
| SCHEMBL5514358 | 0.87 | LMNA (0.46) | CNR1MAPK11MAPK14MAPK1IKBKB | |
| SCHEMBL5520852 | 0.85 | MAPK11 (0.42) | CNR1MAPK11MAPK14MAPK1IKBKB | |
| SCHEMBL14523445 | 0.85 | MEN1 (0.45) | CNR1MAPK11MAPK14MAPK1IKBKB | |
| SCHEMBL5520857 | 0.83 | HSD11B1 (0.41) | CNR1MAPK11MAPK14MAPK1IKBKB | |
| SCHEMBL5514377 | 0.81 | CNR1 (0.46) | CNR1MAPK11MAPK14MAPK1HSD11B1 | |
| SCHEMBL14523442 | 0.78 | CKS1B (0.51) | CNR1MAPK11MAPK14MAPK1 | |
| SCHEMBL14523443 | 0.78 | MAPT (0.48) | CNR1MAPK11MAPK14MAPK1 | |
| SCHEMBL14544903 | 0.77 | CNR1 (0.53) | CNR1MAPK1 | |
| SCHEMBL4694363 | 0.75 | CKS1B (0.53) | CNR1TP53FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885MAPK11 2957/4885MAPK14 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.